McKINNEY, Texas — Soleo Health, an innovative leader in specialty infusion services, announced the company has been selected by Genentech (member of the Roche Group), a world-leading biotechnology company with multiple products on the market and a strong development pipeline, to dispense two limited distribution drugs, Hemlibra and Ocrevus.
Hemlibra (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from the Food and Drug Administration (FDA) in November 2017. Ocrevus (ocrelizumab) is used for patients with relapsing or primary progressive forms of multiple sclerosis and was approved by the FDA in March 2017. Soleo Health has extensive clinical experience in treating patients with these conditions. The company’s highly trained clinical team has engaged in comprehensive training and education for the delivery of these two medications.
As a leading specialty infusion services provider with licensure in 50 states, Soleo Health is quickly gaining expanded access to several limited drug distribution networks as it becomes increasingly recognized for its proven clinical track record, positive patient outcomes and expertise in caring for patients in the home or alternate site setting. Currently, Soleo Health administers the patient care services and delivery of nine limited distribution drugs across multiple therapeutic classes.
“The selection of Soleo Health by Genentech is demonstrative of our exceptional clinical experience and service capabilities. We are pleased to be chosen to administer these important life-changing therapies. Being part of manufacturer limited drug distribution networks expands Soleo Health’s clinical service offering for patients, providers and payors, and helps fuel our continued rapid growth. This is a testament to our reputation and commitment to providing outstanding patient care as well as our dedication to improving clinical outcomes,” explained Craig Vollmer, executive vice president at Soleo Health.